Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Slide resources

Educational resources are an essential component of the mission of PCSK9 Forum to increase awareness and understanding of PCSK9 science and therapeutics.

In addition to the unique slide resources that have been developed by PCSK9 Forum, members of the Editorial Board have kindly shared their own slide resources.

Check back for new postings of these expert-led slide resources.

Slide resource programme

FOURIER trial slide resources

Fourier: Evolocumab and the severity and extent of coronary artery disease Fourier: Evolocumab and the severity and extent of coronary artery disease
Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk
LDL-C lowering with evolocumab and outcomes in patients with PAD: Insights from the FOURIER trial LDL-C lowering with evolocumab and outcomes in patients with PAD: Insights from the FOURIER trial

ODYSSEY trial slide resources

Alirocumab in patients with type 1 and type 2 diabetes: ODYSSEY-DM Insulin trial Alirocumab in patients with type 1 and type 2 diabetes: ODYSSEY-DM Insulin trial
ODYSSEY Outcomes: Background, design, results and interpretation ODYSSEY Outcomes: Background, design, results and interpretation
The ODYSSEY Outcomes trial with alirocumab in acute coronary syndromes The ODYSSEY Outcomes trial with alirocumab in acute coronary syndromes

ORION trial slide resources

Inclisiran and the ORION clinical development program Inclisiran and the ORION clinical development program
PCSK9 inhibition: an overview of therapeutic approaches PCSK9 inhibition: an overview of therapeutic approaches

Background slide resources addressing critical questions in the PCSK9 field

Innovative immunotherapy for hypercholesterolaemia Innovative immunotherapy for hypercholesterolaemia
PCSK9 as a therapeutic target to reduce LDL-C and the burden of ASCVD PCSK9 as a therapeutic target to reduce LDL-C and the burden of ASCVD
Unmet clinical needs in lipid lowering: Focus on LDL-C Unmet clinical needs in lipid lowering: Focus on LDL-C

Familial Hypercholesterolaemia

How do we recognize FH in clinical practice? How do we recognize FH in clinical practice?
FH in children and adolescents FH in children and adolescents
Rutherford 2 in HEFH Rutherford 2 in HEFH
PCSK9 inhibition in homozygous FH PCSK9 inhibition in homozygous FH

More slides from our Editorial Board

Inclisiran and the ORION clinical development programme Inclisiran and the ORION clinical development programme
Evolution of PCSK9 inhibitors: Pipedream or Evidence based Reality Evolution of PCSK9 inhibitors: Pipedream or Evidence based Reality
PCSK9 Inhibitors: A View of Clinical Studies PCSK9 Inhibitors: A View of Clinical Studies
PCSK9 for LDL cholesterol reduction: what have we learned? PCSK9 for LDL cholesterol reduction: what have we learned?
Phase II studies Phase II studies
First in man studies First in man studies
The PCSK9 Revolution The PCSK9 Revolution
ALN-PCSsc: Initial Phase 1 Study Results ALN-PCSsc: Initial Phase 1 Study Results


About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.
Educational Partners and Supporters
Amgen white-box Novartis white-box Sanofi white-box Amgen white-box Novartis white-box Sanofi white-box Amgen white-box Novartis white-box Sanofi white-box Amgen white-box Novartis white-box Sanofi white-box
© Copyright 2023 PCSK9 Forum. All rights reserved